source
- Argenx to buy Forte Biosciences for up to $2.2 billion, adding experimental CD122 drug FB102Argenx announced it will acquire Forte Biosciences in a transaction valued at up to $2.2 billion. The purchase price is set at $77 per Forte share, roughly a 41% premium to the previous closing pr…
- MapLight shares plunge 66% after mid-stage schizophrenia trial shows modest benefit but raises competitive concernsMapLight Therapeutics announced results from its mid‑stage trial of an experimental schizophrenia drug. The study enrolled adults experiencing an acute exacerbation of psychotic symptoms. The twic…